INHIBITION OF BONE TUMOR FORMATION USING cDNA ANTISENSE THERAPY

ROBERT L. GENDRON
HÉLÈNE PARADIS

ABSTRACT

As described herein, the present invention comprises a method for using tubedown-1 (tbdn-1) antisense reagents as gene therapy agents for the treatment of bone tumors and Ewing's sarcoma family of tumors. Antisense-based reagents, such as tbdn-1 antisense construct or biologically stabilized oligonucleotides, or any compound which would elicit the downregulation of tbdn-1 level or activity and the same biological effects as tbdn-1 antisense construct on bone tumor growth in vivo provide valuable alternative or supplemental therapies for bone cancer.